FIG. 5.
MRI analysis of muscle morphology in GRMD canines. (A) The CSAmax of MG, LG, FDS, TC, and EDL at baseline (month 0) and at monthly time points post injection of 1.7×1012 gc/kg scAAV8-dnMSTAT with liver-specific promoter for 6 months and at 1 year. Plots represent mean values, with error bars omitted for clarity (n=4). (B) The CSAmax of GRMD canines at 13 months post injection (n=4) was compared with untreated, age-matched GRMD controls (n=3) (21–25 months of age). *p<0.05 vs. control. (C) The AC compartment volume (TC+EDL) of treated GRMD canines was also measured at each time point (n=4) and (D) compared with age-matched, untreated GRMD controls (n=3) at 13 months post injection. *p<0.05 vs. control. Values are means±SEM.